COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk said on Wednesday it will sharpen its commercial focus and reduce costs, ...

Sales of Novo Nordisk’s diabetes drugs including Ozempic slowed to grow at 8 per cent year on year in the first half, down sharply from its rate last year, as the company loses market share to rival ...

Novo Nordisk A/S’s earnings rose less than expected in the second quarter as the Danish drugmaker contends with competition ...

Sales within Diabetes and Obesity care increased by 16% in Danish kroner to DKK 145.4 billion (18% at CER), mainly driven by Obesity care growth of 56% in Danish kroner to DKK 38.8 billion (58% at CER ...